Advertisement
Correspondence| Volume 52, ISSUE 4, P470-471, April 2020

Download started.

Ok

Reply to Comment: Is there any place for SGLT2-inhibitors in post-liver transplantation patients?

  • Giuseppina Pisano
    Correspondence
    Corresponding author.
    Affiliations
    Unit of Medicine and Metabolic Disease, Department of Pathophysiology and Transplantation Fondazione Ca' Granda IRCCS, Ospedale Maggiore Policlinico University of Milan, Milan, Italy
    Search for articles by this author
  • Francesca Donato
    Affiliations
    Division of Gastroenterology and Hepatology, Unit of Transplant Hepatology, RC AM and A Migliavacca Center for the Study of Liver Disease, Fondazione Ca' Granda IRCCS, Ospedale Maggiore Policlinico, Italy
    Search for articles by this author
  • Rosa Lombardi
    Affiliations
    Unit of Medicine and Metabolic Disease, Department of Pathophysiology and Transplantation Fondazione Ca' Granda IRCCS, Ospedale Maggiore Policlinico University of Milan, Milan, Italy
    Search for articles by this author
  • Daniele Dondossola
    Affiliations
    Unit of Hepatic Surgery, Department of Pathophysiology and Transplantation, Fondazione Ca' Granda IRCCS, Ospedale Maggiore Policlinico University of Milan, Milan, Italy
    Search for articles by this author
  • Emanuela Orsi
    Affiliations
    Endocrinology and Diabetes Unit, Ca' Granda IRCCS Foundation, Policlinico Hospital, Department of Medical Science, University of Milan, Italy
    Search for articles by this author
  • Anna Ludovica Fracanzani
    Affiliations
    Unit of Medicine and Metabolic Disease, Department of Pathophysiology and Transplantation Fondazione Ca' Granda IRCCS, Ospedale Maggiore Policlinico University of Milan, Milan, Italy
    Search for articles by this author
Published:February 13, 2020DOI:https://doi.org/10.1016/j.dld.2020.01.007
      We were pleased to read the letter by Dr Patoulias, “Is there any place for sodium-glucose co-transporter 2 inhibitors in post-liver transplantation patients?”, commenting our study. We agree with the Authors on the possible beneficial effect of SGLT2-inhibitors use for patients who underwent orthotropic liver transplantation (OLT), given the absolute need for new therapeutic strategies able to prevent cardiac and atherosclerotic damage.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lo K.B.
        • Gul F.
        • Ram P.
        • Kluger A.Y.
        • Tecson K.M.
        • McCullough P.A.
        • Rangaswami J.
        The effects of Q1620 SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis.
        Cardiorenal Med. 2020; 10: 1-10
        • Chilton R.
        • Tikkanen I.
        • Cannon C.P.
        • Crowe S.
        • Woerle H.J.
        • Broedl U.C.
        • et al.
        Effect of empaglifozin on blood pressure and markers of arterial stiffness and vascular resistance in patiens with type 2 diabetes.
        Diabetes Obes Metab. 2015; 17: 1180-1193
        • Tanaka A.
        • Murohara T.
        • Taguchi I.
        • Eguchi K.
        • Suzuki M.
        • Kitakaze M.
        • et al.
        Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
        Cardiovasc Diabetol. 2016; 15: 133
        • Tanaka H.
        • Soga F.
        • Tatsumi K.
        • Mochizuki Y.
        • Sano H.
        • Toki H.
        • et al.
        Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
        Cardiovasc Diabetol. 2020; 19: 6
        • Neeland I.J.
        • McGuire D.K.
        • Clinton R.
        • Crowe S.
        • Lund S.S.
        • Woerle H.J.
        • et al.
        Empaglifozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.
        Diab Vasc Dis Res. 2016; 13: 119-126
        • Sato T.
        • Aizawa Y.
        • Yuasa S.
        • Kishi S.
        • Fuse K.
        • Fujita S.
        • et al.
        The effect of dapaglifozin treatment on epicardial adipose tissue volume.
        Cardiovasc Diabetol. 2018; 17: 6

      Linked Article

      • Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?
        Digestive and Liver DiseaseVol. 52Issue 2
        • Preview
          we read with great interest the results of the prospective study conducted by Pisano and colleagues, concerning the early onset of atherosclerotic and cardiac damage after liver transplantation [1]. The researchers observed a significant increase in indices such as carotid intima-media thickness (cIMT), epicardial adipose tissue (EAT) and cardiac diastolic dysfunction, as assessed by the early diastolic (E-wave)/late diastolic (A-wave) ratio (E/A) and a non-significant increase in carotid-femoral pulse wave velocity (PWV), the established “gold-standard” of arterial stiffness, in a cohort of 50 patients that underwent liver transplantation [1].
        • Full-Text
        • PDF
      • High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation: Preliminary results
        Digestive and Liver DiseaseVol. 52Issue 1
        • Preview
          Liver transplanted patients are at high risk of metabolic syndrome and its complications. We aimed to prospectively evaluate the early onset of cardiovascular alterations in patients submitted to the transplant waiting list. From January 2014 to January 2016, 54 out of 79 patients on the waiting list with decompensated cirrhosis or hepatocellular-carcinoma received the transplant, 50 were followed for 24 months, 2 died post-surgery and 2 were lost to follow-up. A significantly increased prevalence of visceral adiposity (epicardial adipose tissue thickness (p = 0.001) and worsening of carotid damage (p = 0.003) and diastolic dysfunction (E/A p = 0.001) was observed at 6 months after transplant and remained stable at 24 months, corresponding to an increased prevalence of diabetes, metabolic syndrome, hypertension and dyslipidemia.
        • Full-Text
        • PDF